(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How to Build a Yard That Helps Monarchs During Spring Migration - 2Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- 3Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- 46 Pet Sitting Administrations for Your Cherished Pets
- 525 Most Beautiful Villages in France You Can Actually Visit
- Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- Israel's haredi draft crisis: Court ruling and political stalemate reach breaking point
- Air Force made critical errors during October 7 massacre, investigator says
- Is Chinese food truly flavorful?
- What to know about the "wild, wild West" of viral peptide claims
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- Drenched in Pixels: A Survey of \Vivid Interactivity Experience\ Game
- Pick Your Favored kind of sandwich
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
